(Q37850519)

24 August 2017

1 reference

title

Natural products and the search for novel vaccine adjuvants (English)

1 reference

24 August 2017

0 references

1 reference

4

Donald P McManus

1 reference

24 August 2017

Jose Rey-Ladino

1

1 reference

24 August 2017

Allen G Ross

series ordinal

2

1 reference

24 August 2017

Allan W Cripps

series ordinal

3

1 reference

24 August 2017

Ronald Quinn

series ordinal

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

23 July 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

38

1 reference

24 August 2017

page(s)

6464-6471

1 reference

24 August 2017

cites work

The science of adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Bridging the knowledge gaps in vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Dendritic cells in vivo: a key target for a new vaccine science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Mechanism of action of licensed vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Pathogen recognition and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Impact of natural products on developing new anti-cancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

New aspects of natural products in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Natural products as sources of new drugs over the last 25 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-like receptors and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Pattern recognition receptors and control of adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Approaching the asymptote? Evolution and revolution in immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Activating immunity: lessons from the TLRs and NLRs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Activation of dendritic cells: translating innate into adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Function of Nod-like receptors in microbial recognition and host defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Nod-like proteins in immunity, inflammation and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Nod1-Mediated Innate Immune Recognition of Peptidoglycan Contributes to the Onset of Adaptive Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The inflammasomes: guardians of the body

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The inflammasome: a danger sensing complex triggering innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The fungal pattern recognition receptor, Dectin-1, and the associated cluster of C-type lectin-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Myeloid C-type lectins in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The mannose-binding lectin: a prototypic pattern recognition molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Directly transfected langerin+ dermal dendritic cells potentiate CD8+ T cell responses following intradermal plasmid DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The macrophage mannose receptor induces IL-17 in response to Candida albicans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Differential antigen processing by dendritic cell subsets in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Regulation of adaptive immunity by the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

MyD88-dependent pathway in T cells directly modulates the expansion of colitogenic CD4+ T cells in chronic colitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Structure and function of Toll receptors and their ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Leucine-rich repeats and pathogen recognition in Toll-like receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Triggering TLR signaling in vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

In the absence of IL-12, CD4(+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(-/-) setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-dependent control mechanisms of CD4 T cell activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Control of B-cell responses by Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-like receptors control activation of adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The immune gene repertoire encoded in the purple sea urchin genome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Molecular diversity at the plant-pathogen interface.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Recent insights into R gene evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Host-microbe interactions: shaping the evolution of the plant immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Genome-wide analysis of NBS-LRR-encoding genes in Arabidopsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Global expression analysis of nucleotide binding site-leucine rich repeat-encoding and related genes in Arabidopsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Plant pathogens and integrated defence responses to infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Plants compared to animals: the broadest comparative study of development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The C-type lectin-like domain superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Cflec-4, a multidomain C-type lectin involved in immune defense of Zhikong scallop Chlamys farreri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Specificity of the innate immune system and diversity of C-type lectin domain (CTLD) proteins in the nematode Caenorhabditis elegans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

A new C-type lectin (FcLec5) from the Chinese white shrimp Fenneropenaeus chinensis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Mitogen-activated protein kinase pathways defend against bacterial pore-forming toxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-like receptors are part of the innate immune defense system of sponges (demospongiae: Porifera).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Innate immune defense of the sponge Suberites domuncula against bacteria involves a MyD88-dependent signaling pathway. Induction of a perforin-like molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

A reverse genetic analysis of components of the Toll signaling pathway in Caenorhabditis elegans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Plant perception systems for pathogen recognition and defence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Flagellin perception: a paradigm for innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Innate immunity in plants and animals: striking similarities and obvious differences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

RRS1 and RPS4 provide a dual Resistance-gene system against fungal and bacterial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The Arabidopsis RPS4 bacterial-resistance gene is a member of the TIR-NBS-LRR family of disease-resistance genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

T-cell-immunity-based inhibitory effects of orally administered herbal medicine juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

(-)-Epigallocatechin-3-gallate prevents photocarcinogenesis in mice through interleukin-12-dependent DNA repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates TH1/TH2 responses in a murine model of allergic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Amplified immune response by ginsenoside-based nanoparticles (ginsomes).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Evaluation of widely consumed botanicals as immunological adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Invariant NKT cells sustain specific B cell responses and memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Sp185/333: a novel family of genes and proteins involved in the purple sea urchin immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Macroarray analysis of coelomocyte gene expression in response to LPS in the sea urchin. Identification of unexpected immune diversity in an invertebrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Pathogen recognition by innate immunity and its signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Toll-like receptors as adjuvant receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Developing a drug-like natural product library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The evolving role of natural products in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Marine natural product libraries for high-throughput screening and rapid drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Protein structure similarity clustering and natural product structure as guiding principles in drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Direct screening of natural product extracts using mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Regulatory T cells and IL-10 in allergic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Exploiting dendritic cells to improve vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Dendritic cells break bonds to tolerize

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Tolerogenic dendritic cells and the quest for transplant tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Monocytes from HTLV-1-infected patients are unable to fully mature into dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Simian virus 40 inhibits differentiation and maturation of rhesus macaque DC-SIGN(+) dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.041

10.1016/J.VACCINE.2011.07.041

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference